Syneos Health (Nasdaq:SYNH) - Cours de l'action, nouvelles et analyse

SYNH Aperçu des actions

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company.

SYNH analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	3/6
Performances passées	1/6
Santé financière	3/6
Dividendes	0/6

Récompenses

Se négocie à 25.3% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 33.7% par an

Analyse des risques

La dette n’est pas bien couverte par le flux de trésorerie opérationnel

Des éléments non récurrents importants ayant un impact sur les résultats financiers

Les marges bénéficiaires (1.3%) sont inférieures à celles de l'année dernière (5.1%)

Syneos Health, Inc. Concurrents

Sotera Health

NasdaqGS:SHC

US$4.5b

Stevanato Group

NYSE:STVN

US$5.1b

Bruker

NasdaqGS:BRKR

US$8.8b

Charles River Laboratories International

NYSE:CRL

US$9.5b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Syneos Health
Historique des cours de bourse
Prix actuel de l'action	US$42.98
Plus haut sur 52 semaines	US$52.23
Plus bas sur 52 semaines	US$22.89
Bêta	1.58
1Variation sur 1 mois	0.66%
Variation sur 3 mois	1.99%
Variation sur 1 an	-8.84%
3Variation sur 3 ans	-23.06%
Variation sur 5 ans	-10.61%
Évolution depuis l'introduction en bourse	109.76%

Nouvelles et mises à jour récentes

Recent updates

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Jun 18

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Jun 03

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

May 19

Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Apr 08

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Mar 27

Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Mar 05

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Feb 18

Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

Feb 03

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting

Jan 04

Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022

Dec 03

Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Dec 03

Rendement pour les actionnaires

	SYNH	US Life Sciences	US Marché
7D	0.6%	-3.5%	0.5%
1Y	-8.8%	20.9%	36.8%

Rendement vs Industrie: SYNH a dépassé le secteur US Life Sciences qui a rapporté 20.9 % au cours de l'année écoulée.

Rendement vs marché: SYNH a sous-performé le marché US qui a rapporté 36.8 % au cours de l'année écoulée.

Volatilité des prix

Is SYNH's price volatile compared to industry and market?
SYNH volatility
SYNH Average Weekly Movement	0.3%
Life Sciences Industry Average Movement	8.1%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.0%

Cours de l'action stable: SYNH n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de SYNH a diminué de 9% à 0% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2010	28,768	Michelle Keefe	www.syneoshealth.com

Syneos Health, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Syneos Health se comparent-ils à sa capitalisation boursière ?
SYNH statistiques fondamentales
Capitalisation boursière	US$4.46b
Bénéfices(TTM)	US$71.22m
Recettes(TTM)	US$5.42b

62.6x

Ratio P/E

0.8x

Ratio P/S

Le site SYNH est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
SYNH compte de résultat (TTM)
Recettes	US$5.42b
Coût des recettes	US$4.22b
Marge brute	US$1.20b
Autres dépenses	US$1.13b
Les revenus	US$71.22m

Derniers bénéfices déclarés

Jun 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	0.69
Marge brute	22.14%
Marge bénéficiaire nette	1.31%
Ratio dettes/capitaux propres	75.8%

Quelles ont été les performances à long terme de SYNH?

Voir les performances historiques et les comparaisons

SYNH Aperçu des actions

Récompenses

Analyse des risques

Syneos Health, Inc. Concurrents

NasdaqGS:SHC

US$4.5b

NYSE:STVN

US$5.1b

NasdaqGS:BRKR

US$8.8b

NYSE:CRL

US$9.5b

Historique des prix et performances

Nouvelles et mises à jour récentes

Syneos Health, Inc. Announces Board Appointments

Syneos Health Files Form 15

Syneos Health, Inc. Announces Chief Executive Officer Changes

Syneos Health, Inc. Announces Management Changes

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Recent updates

Syneos Health, Inc. Announces Board Appointments

Syneos Health Files Form 15

Syneos Health, Inc. Announces Chief Executive Officer Changes

Syneos Health, Inc. Announces Management Changes

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Levi & Korsinsky Notifies Syneos Health, Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Consensus EPS estimates fall by 70%

The Klein Law Firm Announces That a Class Action Complaint Has Been Filed on Behalf of Shareholders of Syneos Health, Inc

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Syneos Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Syneos Health, Inc

Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer

Syneos Health, Inc. Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity

Consensus EPS estimates fall from profit to US$0.31 loss, revenue upgraded

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C entered into an agreement to acquire Syneos Health, Inc. (NasdaqGS:SYNH) in a transaction valued at approximately $7.5 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?

Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Syneos Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 11%

Price target decreased by 10% to US$36.95

Syneos Health, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Syneos Health, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?

Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?

High number of new directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors

Syneos Health Adds Hub Patient Suite to Deployment Solutions Business

Syneos Health, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Syneos Health, Inc. Announces Executive Changes

Price target decreased to US$69.73

Syneos, Datavant expand partnership on data analytics for clinical trials

Investor sentiment deteriorated over the past week

Syneos Health falls 13% after update on outlook

When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Syneos Health, Inc. (NasdaqGS:SYNH) acquired Boco Digital Media, LLC.

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Provides Earnings Guidance for the Third Quarter of 2022

Syneos Health Q2 2022 Earnings Preview

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case

Syneos Health, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Syneos: Upside Could Be Priced In, Valuations Unsupportive

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

Consensus forecasts updated

High number of new directors

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings: EPS misses analyst expectations

Syneos Health Announces Executive Promotions

Syneos Health, Inc., Annual General Meeting, May 25, 2022